• In this post-hoc analysis of the TAMDMD trial among 14 boys, median 11 years of age, treated with either tamoxifen or placebo for 48 weeks, treatment was well-tolerated. • A visual trend of improved left-ventricular dimensions and better systolic function preservation generates the hypothesis of a potential beneficial effect of tamoxifen in DMD cardiomyopathy.
Keyphrases
- duchenne muscular dystrophy
- left ventricular
- breast cancer cells
- heart failure
- estrogen receptor
- positive breast cancer
- phase iii
- muscular dystrophy
- blood pressure
- acute myocardial infarction
- clinical trial
- hypertrophic cardiomyopathy
- mitral valve
- study protocol
- cardiac resynchronization therapy
- aortic stenosis
- left atrial
- randomized controlled trial
- risk assessment
- human health
- combination therapy
- gestational age
- replacement therapy